Steven H. Olson MD
Clinical Informatics
Retired Regional Physician Director of The Permanente Medical Group
Join to View Full Profile
RETIRED 401 Bicentennial WaySanta Rosa, CA 95403
Phone+1 707-571-4000
Dr. Olson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Sutter Health/Sutter Santa Rosa Regional HospitalResidency, Family Medicine, 1984 - 1987
University of California, Davis, School of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 1985 - 2027
American Board of Preventive Medicine Clinical Informatics
Publications & Presentations
PubMed
- 21 citationsKinetics of α-synuclein prions preceding neuropathological inclusions in multiple system atrophy.Amanda L. Woerman, Smita S. Patel, Sabeen A. Kazmi, Abby Oehler, Jisoo Lee
Plos Pathogens. 2020-02-04 - 5 citationsDiscovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 ActivityJean-Marc M Grandjean, Alexander Y Jiu, John W West, Atsushi Aoyagi, Daniel G Droege
ACS Medicinal Chemistry Letters. 2020-01-30 - 64 citationsMultiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines.Amanda L. Woerman, Abby Oehler, Sabeen A. Kazmi, Jisoo Lee, Glenda M. Halliday
Acta Neuropathologica. 2019-01-28
Grant Support
- Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probesUNIVERSITY OF MINNESOTA2024–2029
- Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of CancerSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2024–2029
- Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of CancerSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2024–2029
- Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probesUNIVERSITY OF MINNESOTA2024–2029
- GCDH Addiction in MelanomaSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2022–2027
- GCDH Addiction in MelanomaSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2022–2027
- Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathiesSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2022–2025
- Small molecule inhibitors of LMPTP: an obesity drug targetCEDARS-SINAI MEDICAL CENTER2022–2025
- Small molecule inhibitors of LMPTP: an obesity drug targetCEDARS-SINAI MEDICAL CENTER2022–2025
- Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathiesSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2022–2025
- Targeting neuroinflammation in AD with novel CX3CR1 agonistsSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
